Second-line chemotherapy for refractory cancer: intraperitoneal chemotherapy

Area of Science:

• Gynecologic Oncology
• Cancer Therapeutics
• Pharmacokinetics

Background:

• Intraperitoneal (IP) therapy for ovarian cancer has transitioned from a theoretical concept to a practical treatment strategy.
• Its application is now targeted towards specific patient populations.
• Ovarian cancer management continues to evolve with innovative therapeutic approaches.

Purpose of the Study:

• To evaluate the role of intraperitoneal therapy in ovarian cancer management.
• To identify patient subsets most likely to benefit from IP therapy.
• To define criteria for selecting patients for IP treatment strategies.

Main Methods:

• Review of the evolution and application of intraperitoneal therapy in ovarian cancer.
• Identification of patient characteristics suitable for IP treatment, specifically small-volume residual disease (< or = 0.5 cm).
• Analysis of factors predicting response to salvage platinum-based IP therapy, including prior systemic chemotherapy response.

Main Results:

• Intraperitoneal therapy is a rational strategy for patients with small-volume residual ovarian cancer.
• Patients with microscopic disease or largest tumor nodules <= 0.5 cm are candidates.
• A prior response to systemic cisplatin or carboplatin is a key indicator for successful salvage IP therapy.

Conclusions:

• Intraperitoneal therapy is an effective treatment strategy for select ovarian cancer patients.
• Patient selection based on residual disease volume and prior chemotherapy response is crucial.
• This regional approach offers a valuable option in the management of ovarian cancer.